In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Celgene licenses Thalomid to Pharmion

Executive Summary

Celgene (small-molecule drugs for cancer and immunological diseases) has licensed Thalomid (thalidomide) to Pharmion (focuses on hematology and oncology therapeutics) to treat cancer and inflammatory diseases in foreign markets excluding Canada, China, Japan, Taiwan, and Korea.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Concluded
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing
    • Includes Equity

Related Companies

Advertisement
UsernamePublicRestriction

Register